AUTHOR=Bernardi Chiara , Beauverd Yan , Tran Thien An , Maulini Marie , Mappoura Maria , Morin Sarah , Simonetta Federico , Cairoli Anne , Auner Holger W. , Samii Kaveh , Chalandon Yves , de Ramon Ortiz Carmen 

TITLE=Anti-BCMA and GPRC5D bispecific antibodies in relapsed/refractory primary plasma cell leukemia: a case report

JOURNAL=Frontiers in Immunology

VOLUME=Volume 15 - 2024

YEAR=2024

URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1495233

DOI=10.3389/fimmu.2024.1495233

ISSN=1664-3224

ABSTRACT=Plasma cell leukemia (PCL) is an aggressive and high-risk variant of multiple myeloma (MM) with a very poor prognosis. Given its rarity and aggressiveness, there is a lack of clinical trials testing the efficacity of novel therapies in these patients. New immune approaches such as B-cell maturation antigen (BCMA) and G protein-coupled receptor, family C, group 5, member D (GPRC5D) -targeting agents, including chimeric antigen receptor (CAR) T-cells and bispecific antibodies could play a role in PCL treatment. However, PCL patients were excluded from recent pivotal clinical trials testing those agents and only some case reports have been published. We present here the clinical course of a patient with relapsed/refractory (R/R) primary (p) PCL who was treated with anti-BCMA and anti-GPRC5D bispecific antibodies at our center.